Chris Holmes

VP CMC Operations

Apellis Pharmaceuticals


Chris received his Ph.D in organic chemistry from UC Berkeley and trained as a discovery/medicinal chemist. He transferred to development/CMC in 2001 while at Affymax where he led the CMC tasks that led to the commercialization of Omontys, the first approved PEGylated synthetic peptide. Since 2017 he has been VP of CMC/process chemistry at Apellis working with another PEGylated peptide pegcetacoplan which has led to two recent product approvals : Empaveli and Syfovre. Chris has become a subject matter expert for PEGylated conjugates.